Radio-223 radiotherapy
What is it?
Radium 223 is an alpha-emitting drug, characterized by high power and a small range of action that allows it to destroy only tumor cells that are in close proximity to the target. Radium 223 is the first radiopharmaceutical with specific action on bone tissue that, in addition to delaying skeletal complications, increases bone survival.
When is this exam indicated?
Bone metastases of castration-resistant prostate cancer.
How is it performed?
Ra-223 is administered intravenously by slow injection (generally up to 1 minute) at intervals of 4 weeks ± 7 days for 6 injections. Unless clinical necessary, discharge will be within the same day. The most frequently observed adverse reactions (≥10%) in patients treated with Ra-223 were diarrhea, nausea, vomiting, and thrombocytopenia. The most serious adverse reactions were thrombocytopenia and neutropenia. Hypersensitivity reactions including anaphylactic and anaphylactoid allergic reactions are also possible, although they occur rarely.
Contraindications
There are no known contraindications to the use of Ra-223.
Where do we treat it?
Our Departments
Are you interested in receiving the treatment?